ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 426

Exploring the DAS: What Is the Level of Agreement in the Classification of Remission and Low Disease Activity (LDA) Among the Various Versions of the Disease Activity Score (DAS) and Their Correlation? an Analysis from a Prospective, Observational Registry

WG Bensen1, Edward Keystone2, Philip Baer3, Jude Rodrigues4, J. Antonio Avina-Zubieta5, Wojciech Olszynski6, Denis Choquette7, Suneil Kapur8, Manisha Mulgund9, John S. Sampalis10, Emmanouil Rampakakis10, Francois Nantel11, Allen J Lehman12, May Shawi11 and Susan Otawa12, 1St Josephs Hospital and McMaster University, Hamilton, ON, Canada, 2Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 3Private Practice, Scarborough, ON, Canada, 4Clinical Research and Arthritis Centre, Windsor, ON, Canada, 5Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, 6University of Saskatchewan, Saskatoon, SK, Canada, 7Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 8Rheumatology, University of Ottawa, Ottawa, ON, Canada, 9Private Practice, Hamilton, ON, Canada, 10JSS Medical Research, Montreal, QC, Canada, 11Janssen Inc., Toronto, ON, Canada, 12Medical Affairs, Janssen Inc., Toronto, ON, Canada

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: assessment and outcomes, Disease Activity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects: Novel Biomarkers and Other Measurements of Disease Activity

Session Type: Abstract Submissions (ACR)

Background/Purpose: Two versions of DAS28 are available, DAS28-4 comprising 4 variables [tender and swollen joint counts, acute phase reactant (APR), and patient global assessment] and DAS28-3 where patient global has been omitted. Despite the difference between DAS28-4 and DAS28-3 thresholds for remission and low disease activity (LDA) are the same. Additionally, the APR used to calculate the DAS may be either ESR or CRP. The aim of this analysis is to describe the agreement between these four possible indices, DAS28-4 ESR, DAS28-4 CRP,  DAS28-3 ESR and DAS28-3 CRP and to compare them in terms of classifying remission and LDA in a real-world, routine clinical care setting.

 

Methods: BioTRAC is an ongoing, prospective registry of patients initiating treatment for RA, AS, or PsA with infliximab or golimumab. In this analysis, data from RA patients who were treated with infliximab between 2002-2014 or with golimumab between 2010-2014 and had available information in all indices were used. The definitions for remission were as follows: DAS28-3/4 <2.6; LDA was defined as: DAS28-3/4 <3.2. Correlation between the different indices was assessed with the Pearson's correlation coefficient (r) and classification agreement was assessed with Cronbach's alpha (CA) and the kappa statistic.

 

Results: Eight hundred sixty nine RA patients who had 3,517 complete assessments were included in the analysis. Non-remission was classified by all indices in 61.4% of cases, while remission was achieved in one (5.9%), two (10.3%), three (5.3%), or all four (17.2%) indices. Similarly, non-LDA was classified by all indices in 46.1% of cases, while LDA was achieved in one (6.2%), two (10.9%), three (5.4%), or all four (31.3%) indices.

Overall, a strong linear positive correlation (r>0.8) was observed between all indices. When looking at the internal consistency in terms of classifying disease state, the CA was 0.905 for remission and 0.923 for LDA suggesting an overall high internal consistency. However, when looking at the individual inter-item correlations (Table 1), the agreement between indices was variable with DAS28-3 CRP and DAS28-4 CRP showing the highest correlation and DAS28-3 ESR and DAS28-4 CRP showing the lowest correlation. When comparing DAS28-4 ESR with DAS28-3 ESR, the latter categorized 16.5% of DAS28-4 ESR remission cases as non-remission and 3.0% of DAS28-4 ESR non-remission cases as remission. With respect to LDA, DAS28-3 ESR categorized 9.1% of DAS28-4 ESR LDA cases as non-LDA and 4.7% of DAS28-4 ESR non-LDA cases as LDA. Similar results were observed with DAS28 CRP.   

 

Conclusion: The results of this analysis show that, despite being highly correlated, variability exists in the classification of remission and LDA by the various DAS indices. These results suggest that decision making based on disease state achieved may vary significantly based on the type of APR used in the DAS index.

 

 

 

 

 

Table 1. Inter-Item Correlation Matrix of DAS Remission / LDA Types

Remission

DAS28-4 ESR

DAS28-4 CRP

DAS28-3 ESR

DAS28-3 CRP

DAS28-4 ESR

–

0.678

0.824

0.670

DAS28-4 CRP

0.678

–

0.589

0.846

DAS28-3 ESR

0.824

0.589

–

0.631

DAS28-3 CRP

0.670

0.846

0.631

–

LDA

 

 

 

 

DAS28-4 ESR

–

0.728

0.864

0.702

DAS28-4 CRP

0.728

–

0.670

0.846

DAS28-3 ESR

0.864

0.670

–

0.696

DAS28-3 CRP

0.702

0.846

0.696

–

 


Disclosure:

W. Bensen,
None;

E. Keystone,

Abbott/AbbVie, Amgen, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Centocor, F. Hoffmann-LaRoche, Genzyme, Merck, Novartis Pharmaceuticals, Pfizer Pharmaceuticals, UCB, Genentech, Janssen,

2,

Abbott/AbbVie, Bristol-Myers Squibb, F. Hoffmann-LaRoche, Merck, Pfizer Pharmaceuticals, UCB, Janssen,

5;

P. Baer,

Janssen Inc.,

5;

J. Rodrigues,

Janssen Inc.,

5;

J. A. Avina-Zubieta,
None;

W. Olszynski,

Janssen Inc.,

5;

D. Choquette,

Notre-Dame Hospital, Quebec, Canada,

3,

AbbVie,

5,

Amgen,

5,

Celgene,

5,

BMS Canada,

5,

Janssen Pharmaceutica Product, L.P.,

5,

Pfizer Inc,

5;

S. Kapur,
None;

M. Mulgund,
None;

J. S. Sampalis,
None;

E. Rampakakis,
None;

F. Nantel,

Janssen Inc.,

3;

A. J. Lehman,

Janssen Inc.,

3;

M. Shawi,

Janssen Inc.,

3;

S. Otawa,

Janssen Inc.,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/exploring-the-das-what-is-the-level-of-agreement-in-the-classification-of-remission-and-low-disease-activity-lda-among-the-various-versions-of-the-disease-activity-score-das-and-their-correlation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology